Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 13/20 | 0.48 |
| ▸ | DRD2 | P14416 | 3/20 | 0.43 |
| ▸ | DRD4 | P21917 | 3/20 | 0.43 |
| ▸ | DRD3 | P35462 | 3/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14098739 | 0.90 | PTGER1 (0.52) | PTGER1DRD2DRD4DRD3CYP2C9 | |
| SCHEMBL5127022 | 0.86 | PTGER1 (0.55) | PTGER1DRD2DRD4DRD3CYP2C9 | |
| SCHEMBL5123511 | 0.85 | PTGER1 (0.47) | PTGER1DRD2DRD4DRD3CYP2C9 | |
| SCHEMBL14098738 | 0.78 | PTGER1 (0.51) | PTGER1DRD2DRD4DRD3CYP2C9 | |
| SCHEMBL14098741 | 0.78 | PTGER1 (0.68) | PTGER1CYP2C9 | |
| SCHEMBL5117064 | 0.77 | PTGER1 (0.64) | PTGER1DRD2DRD4DRD3CYP2C9 | |
| SCHEMBL4724701 | 0.77 | PTGER1 (0.48) | PTGER1DRD2DRD4DRD3CYP2C9 | |
| SCHEMBL14098691 | 0.77 | PTGER1 (0.58) | PTGER1DRD2DRD4DRD3CYP2C9 | |
| SCHEMBL5119773 | 0.76 | PTGER1 (0.54) | PTGER1DRD2DRD4DRD3CYP2C9 | |
| SCHEMBL5123378 | 0.74 | PTGER1 (0.71) | PTGER1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1874776-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PGE2 MEDIATED DISORDERS | GLAXO GROUP LIMITED (GB) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006114274-A1 | OXAZOLE AND THIAZOLE COMPOUNDS AND THEIR USE IN THE TREATMENT OF PGE2 MEDIATED DISORDERS | GLAXO GROUP LIMITED (GB) | 2006-11-02 | — | — | WO | disclosed |